WO2024127321 - ENGINEERED VIRUS-LIKE-PARTICLES FOR TARGETED CAPTURE OF MEMBRANE PROTEINS
National phase entry:
Publication Number
WO/2024/127321
Publication Date
20.06.2024
International Application No.
PCT/IB2023/062716
International Filing Date
14.12.2023
Title **
[English]
ENGINEERED VIRUS-LIKE-PARTICLES FOR TARGETED CAPTURE OF MEMBRANE PROTEINS
[French]
PARTICULES DE TYPE VIRAL MODIFIÉES POUR LA CAPTURE CIBLÉE DE PROTÉINES MEMBRANAIRES
Applicants **
USTAV, Jr., Mart
SIDHU, Sachdev
Inventors
USTAV, Jr., Mart
SIDHU, Sachdev
Priority Data
63/387,302
14.12.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2017 | |
| EPO | Filing, Examination, Granting | 6543 | |
| Japan | Filing, Examination, Granting | 2211 | |
| South Korea | Filing, Examination, Granting | 2127 | |
| USA | Filing, Examination, Granting | 6540 |
Total:
19,438
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed are engineered virus-like-particles (VLPs) and their use. In the VPLs integral plasma membrane proteins are captured and displayed on the surface of a VLP in a native conformation based on an interaction between a viral scaffolding protein fused to a PDZ domain and a synthetic polypeptide in the cytoplasmatic C-terminal tail of the target membrane protein.[French]
L'invention concerne des particules de type viral (VLP) modifiées et leur utilisation. Dans les VPL, des protéines intégrales de membrane plasmatique sont capturées et affichées sur la surface d'une VLP dans une conformation native sur la base d'une interaction entre une protéine d'échafaudage virale fusionnée à un domaine PDZ et un polypeptide synthétique dans la queue C-terminale cytoplasmique de la protéine membranaire cible.